Table 3.
Medication use in subgroups with respect to both the presence of peripheral artery disease and the presence of the metabolic syndrome
| PAD+/MetS+ (n = 57) | PAD+/MetS- (n = 157) | PAD-/MetS+ (n = 55) | PAD-/MetS- (n = 142) | p-value | |
|---|---|---|---|---|---|
| Aspirin (%) |
67.9 |
67.8 |
58.2 |
52.8 |
0.006 |
| Clopidogrel (%) |
26.8 |
31.1 |
3.6 |
4.9 |
<0.001 |
| Metformin (%) * |
30.3 |
5.1 |
9.1 |
5.6 |
0.007 |
| Sulfonyrea (%) * |
24.2 |
3.4 |
3.6 |
5.6 |
0.050 |
| Glitazone (%) * |
6.1 |
0.9 |
0.0 |
0.0 |
0.011 |
| Insulin (%) * |
15.2 |
10.3 |
3.6 |
5.6 |
0.040 |
| Statins (%) |
75.0 |
69.2 |
21.8 |
28.2 |
0.003 |
| Angiotensin Converting Enzyme Inhibitors (%) |
49.1 |
40.1 |
24.5 |
23.9 |
<0.001 |
| Calcium Antagonists (%) |
36.8 |
29.3 |
10.9 |
8.5 |
<0.001 |
| Beta Adrenoreceptor Blocking Agents (%) |
31.6 |
40.1 |
61.8 |
38.0 |
0.459 |
| Angiotensin II Receptor Blocking Agents (%) | 12.3 | 10.8 | 9.1 | 4.9 | 0.042 |
PAD denotes peripheral artery disease.
* Percentage of subjects with type 2 diabetes (n = 87 and 45 in the PAD and in the control group, respectively).